Quality Chemical Industries has launched Africa's first locally manufactured hydroxyurea to combat sickle cell disease. The stakes are unprecedented.
Uganda has achieved a monumental, unprecedented milestone in African pharmaceutical independence with the official launch of the continent’s first locally manufactured hydroxyurea plant. Spearheaded by Quality Chemical Industries Limited, this massive capital investment radically transforms the management of sickle cell disease, promising to slash severe medicine shortages and dramatically lower the prohibitive financial barriers to life-saving treatment.
The state-of-the-art manufacturing facility, located in the industrial hub of Luzira on the outskirts of Kampala, was officially commissioned amid high expectations from the medical community. For decades, the structural inability of African nations to manufacture essential chronic-care drugs has resulted in catastrophic mortality rates. The unveiling of the locally produced drug, branded as 'Sikurea,' decisively shatters that deadly dependency on foreign supply chains